(Q51097201)

29 March 2018

title

Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. (English)

1 reference

29 March 2018

1 reference

Löfberg C

1

1 reference

29 March 2018

Agren H

series ordinal

2

1 reference

29 March 2018

Harro J

series ordinal

3

1 reference

29 March 2018

Oreland L

series ordinal

4

1 reference

29 March 2018

language of work or name

English

0 references

publication date

1 May 1998

1 reference

29 March 2018

European Neuropsychopharmacology

published in

1 reference

29 March 2018

volume

8

1 reference

29 March 2018

issue

2

1 reference

29 March 2018

page(s)

153-157

1 reference

29 March 2018

Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

The cholecystokinin hypothesis of panic and anxiety disorders: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Radioimmunoassay of cholecystokinin: comparison of different tracers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Immunochemical evidence of cholecystokinin-like peptides in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Use of the Research Diagnostic Criteria and the Schedule for Affective Disorders and Schizophrenia to study affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Cholecystokinin in human cerebrospinal fluid: concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Alterations in brain cholecystokinin receptors in suicide victims

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

CCK in animal and human research on anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Two brain cholecystokinin receptors: implications for behavioral actions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Short‐term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the peri‐aqueductal grey and limbic regions of rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Research diagnostic criteria: rationale and reliability

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

Cholecystokinin antianalgesia: safety cues abolish morphine analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2897%2900046-1

7 January 2021

10.1016/S0924-977X(97)00046-1

Identifiers

DOI

1 reference

29 March 2018

1 reference

29 March 2018